1/4 Brief reading break from COVID tweets?
Happy to share new #HTN work in @JAMAInternalMed examining the representativeness of trials underlying 2017 BP guidelines
Takeaway:<1/3 of adults rec'd additional BP meds by guidelines meet trial eligibility
ja.ma/38R5tk5
Happy to share new #HTN work in @JAMAInternalMed examining the representativeness of trials underlying 2017 BP guidelines
Takeaway:<1/3 of adults rec'd additional BP meds by guidelines meet trial eligibility
ja.ma/38R5tk5
2/4 Trials most representative of adults 50-69.
Younger adults not included in trials due to low CV risk - benefit of early intensive BP treatment remains unknown
Older adults often excluded due to comorbidities, limited life expectancy, & impaired cognition.
Younger adults not included in trials due to low CV risk - benefit of early intensive BP treatment remains unknown
Older adults often excluded due to comorbidities, limited life expectancy, & impaired cognition.
3/4 As a PCP, I think a lot about how pop health initiatives anchor us on numeric targets...
Given these evidence gaps, tailoring of BP treatment recs by degree of BP elevation, competing risks, and time to benefit is likely preferable to unwavering adoption of strict targets
Given these evidence gaps, tailoring of BP treatment recs by degree of BP elevation, competing risks, and time to benefit is likely preferable to unwavering adoption of strict targets
4/4 Great multi-institution collaboration with expert mentors including @KBibbinsDomingo @kardiologykazi @michelleodden
@BIDMC_Medicine @UCSF_Epibiostat @SmithBIDMC
@BIDMC_Medicine @UCSF_Epibiostat @SmithBIDMC
